Intravitreal dexamethasone implants facilitate the management of refractory Behçet's uveitis with vasculitis
To investigate the efficacy and safety of dexamethasone (DEX) implant, Ozurdex ®, as an adjunctive treatment for refractory Behçet's uveitis (BU), a total of 61 patients (80 eyes) were included in this cross-sectional study and divided into the non-DEX and DEX groups. After >12 months of tre...
Gespeichert in:
| Veröffentlicht in: | Clinical immunology (Orlando, Fla.) Fla.), 2023-06, Vol.251, p.109633-109633, Article 109633 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 109633 |
|---|---|
| container_issue | |
| container_start_page | 109633 |
| container_title | Clinical immunology (Orlando, Fla.) |
| container_volume | 251 |
| creator | Tao, Tianyu Yang, Shizhao He, Daquan Li, Zhaohuai Chen, Binyao Zhu, Lei Su, Wenru |
| description | To investigate the efficacy and safety of dexamethasone (DEX) implant, Ozurdex ®, as an adjunctive treatment for refractory Behçet's uveitis (BU), a total of 61 patients (80 eyes) were included in this cross-sectional study and divided into the non-DEX and DEX groups. After >12 months of treatment, the improvement in the fluorescein angiography score and vitritis score was significantly higher in the DEX group than in the non-DEX group. Although the posterior capsule opacification score was exacerbated, the rate of low-dose systemic glucocorticoid was higher and the relapse times were fewer in the DEX group. Therefore, Ozurdex® is an effective and safe option for patients with BU that are refractory to systemic immunosuppressant treatments by controlling vasculitis, stabilizing vitreous inflammation, preventing recurrence, and reducing daily glucocorticoid doses.
•Dexamethasone intravitreal implants are an effective and safe option for glucocorticoid-resistant Behcet's uveitis. |
| doi_str_mv | 10.1016/j.clim.2023.109633 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2811215838</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1521661623001328</els_id><sourcerecordid>2811215838</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-c125963a15962c160f496826b1ced20cdae58731dfee56d75c7e07c41a81c283</originalsourceid><addsrcrecordid>eNp9kM1OAyEUhYnRWP9ewIVhp5tWLlOYaeJGG_-SJm66J5S5Y2mGmQpM1SfyQXwxmbS6dANccs7JPR8h58BGwEBer0amtm7EGc_Sx0Rm2R45AsFhmLNM7O_eUoIckOMQVowxwbk8JIMsB8H4GI6Ie26i1xsbPeqalvihHcalDm2D1Lp1rZsYaKWNrW3UEWlcInW60a_osIm0rajHymsTW_9J73D5_YXxMtBugzbaQN9tXNKNDqar-_mUHFS6Dni2u0_I_OF-Pn0azl4en6e3s6EZMxaHBrhIdTSkkxuQrBpPZMHlAgyWnJlSoyjyDMoKUcgyFyZHlpsx6AIML7ITcrWNXfv2rcMQlbPBYJ3aYNsFxQsADqLIeinfSo1vQ0hd1Npbp_2nAqZ6ymqlesqqp6y2lJPpYpffLRyWf5ZfrElwsxVgKrmx6FUwFpu0vfVooipb-1_-D1BnkGM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2811215838</pqid></control><display><type>article</type><title>Intravitreal dexamethasone implants facilitate the management of refractory Behçet's uveitis with vasculitis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Tao, Tianyu ; Yang, Shizhao ; He, Daquan ; Li, Zhaohuai ; Chen, Binyao ; Zhu, Lei ; Su, Wenru</creator><creatorcontrib>Tao, Tianyu ; Yang, Shizhao ; He, Daquan ; Li, Zhaohuai ; Chen, Binyao ; Zhu, Lei ; Su, Wenru</creatorcontrib><description>To investigate the efficacy and safety of dexamethasone (DEX) implant, Ozurdex ®, as an adjunctive treatment for refractory Behçet's uveitis (BU), a total of 61 patients (80 eyes) were included in this cross-sectional study and divided into the non-DEX and DEX groups. After >12 months of treatment, the improvement in the fluorescein angiography score and vitritis score was significantly higher in the DEX group than in the non-DEX group. Although the posterior capsule opacification score was exacerbated, the rate of low-dose systemic glucocorticoid was higher and the relapse times were fewer in the DEX group. Therefore, Ozurdex® is an effective and safe option for patients with BU that are refractory to systemic immunosuppressant treatments by controlling vasculitis, stabilizing vitreous inflammation, preventing recurrence, and reducing daily glucocorticoid doses.
•Dexamethasone intravitreal implants are an effective and safe option for glucocorticoid-resistant Behcet's uveitis.</description><identifier>ISSN: 1521-6616</identifier><identifier>EISSN: 1521-7035</identifier><identifier>DOI: 10.1016/j.clim.2023.109633</identifier><identifier>PMID: 37150241</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Behcet Syndrome - complications ; Behcet Syndrome - drug therapy ; Behçet's disease ; Cross-Sectional Studies ; Dexamethasone ; Dexamethasone - therapeutic use ; Glucocorticoids - therapeutic use ; Humans ; Ozurdex ; Retrospective Studies ; Treatment Outcome ; Uveitis ; Uveitis - drug therapy ; Vasculitis</subject><ispartof>Clinical immunology (Orlando, Fla.), 2023-06, Vol.251, p.109633-109633, Article 109633</ispartof><rights>2023 The Authors</rights><rights>Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c400t-c125963a15962c160f496826b1ced20cdae58731dfee56d75c7e07c41a81c283</citedby><cites>FETCH-LOGICAL-c400t-c125963a15962c160f496826b1ced20cdae58731dfee56d75c7e07c41a81c283</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1521661623001328$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37150241$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tao, Tianyu</creatorcontrib><creatorcontrib>Yang, Shizhao</creatorcontrib><creatorcontrib>He, Daquan</creatorcontrib><creatorcontrib>Li, Zhaohuai</creatorcontrib><creatorcontrib>Chen, Binyao</creatorcontrib><creatorcontrib>Zhu, Lei</creatorcontrib><creatorcontrib>Su, Wenru</creatorcontrib><title>Intravitreal dexamethasone implants facilitate the management of refractory Behçet's uveitis with vasculitis</title><title>Clinical immunology (Orlando, Fla.)</title><addtitle>Clin Immunol</addtitle><description>To investigate the efficacy and safety of dexamethasone (DEX) implant, Ozurdex ®, as an adjunctive treatment for refractory Behçet's uveitis (BU), a total of 61 patients (80 eyes) were included in this cross-sectional study and divided into the non-DEX and DEX groups. After >12 months of treatment, the improvement in the fluorescein angiography score and vitritis score was significantly higher in the DEX group than in the non-DEX group. Although the posterior capsule opacification score was exacerbated, the rate of low-dose systemic glucocorticoid was higher and the relapse times were fewer in the DEX group. Therefore, Ozurdex® is an effective and safe option for patients with BU that are refractory to systemic immunosuppressant treatments by controlling vasculitis, stabilizing vitreous inflammation, preventing recurrence, and reducing daily glucocorticoid doses.
•Dexamethasone intravitreal implants are an effective and safe option for glucocorticoid-resistant Behcet's uveitis.</description><subject>Behcet Syndrome - complications</subject><subject>Behcet Syndrome - drug therapy</subject><subject>Behçet's disease</subject><subject>Cross-Sectional Studies</subject><subject>Dexamethasone</subject><subject>Dexamethasone - therapeutic use</subject><subject>Glucocorticoids - therapeutic use</subject><subject>Humans</subject><subject>Ozurdex</subject><subject>Retrospective Studies</subject><subject>Treatment Outcome</subject><subject>Uveitis</subject><subject>Uveitis - drug therapy</subject><subject>Vasculitis</subject><issn>1521-6616</issn><issn>1521-7035</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM1OAyEUhYnRWP9ewIVhp5tWLlOYaeJGG_-SJm66J5S5Y2mGmQpM1SfyQXwxmbS6dANccs7JPR8h58BGwEBer0amtm7EGc_Sx0Rm2R45AsFhmLNM7O_eUoIckOMQVowxwbk8JIMsB8H4GI6Ie26i1xsbPeqalvihHcalDm2D1Lp1rZsYaKWNrW3UEWlcInW60a_osIm0rajHymsTW_9J73D5_YXxMtBugzbaQN9tXNKNDqar-_mUHFS6Dni2u0_I_OF-Pn0azl4en6e3s6EZMxaHBrhIdTSkkxuQrBpPZMHlAgyWnJlSoyjyDMoKUcgyFyZHlpsx6AIML7ITcrWNXfv2rcMQlbPBYJ3aYNsFxQsADqLIeinfSo1vQ0hd1Npbp_2nAqZ6ymqlesqqp6y2lJPpYpffLRyWf5ZfrElwsxVgKrmx6FUwFpu0vfVooipb-1_-D1BnkGM</recordid><startdate>202306</startdate><enddate>202306</enddate><creator>Tao, Tianyu</creator><creator>Yang, Shizhao</creator><creator>He, Daquan</creator><creator>Li, Zhaohuai</creator><creator>Chen, Binyao</creator><creator>Zhu, Lei</creator><creator>Su, Wenru</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202306</creationdate><title>Intravitreal dexamethasone implants facilitate the management of refractory Behçet's uveitis with vasculitis</title><author>Tao, Tianyu ; Yang, Shizhao ; He, Daquan ; Li, Zhaohuai ; Chen, Binyao ; Zhu, Lei ; Su, Wenru</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-c125963a15962c160f496826b1ced20cdae58731dfee56d75c7e07c41a81c283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Behcet Syndrome - complications</topic><topic>Behcet Syndrome - drug therapy</topic><topic>Behçet's disease</topic><topic>Cross-Sectional Studies</topic><topic>Dexamethasone</topic><topic>Dexamethasone - therapeutic use</topic><topic>Glucocorticoids - therapeutic use</topic><topic>Humans</topic><topic>Ozurdex</topic><topic>Retrospective Studies</topic><topic>Treatment Outcome</topic><topic>Uveitis</topic><topic>Uveitis - drug therapy</topic><topic>Vasculitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tao, Tianyu</creatorcontrib><creatorcontrib>Yang, Shizhao</creatorcontrib><creatorcontrib>He, Daquan</creatorcontrib><creatorcontrib>Li, Zhaohuai</creatorcontrib><creatorcontrib>Chen, Binyao</creatorcontrib><creatorcontrib>Zhu, Lei</creatorcontrib><creatorcontrib>Su, Wenru</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical immunology (Orlando, Fla.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tao, Tianyu</au><au>Yang, Shizhao</au><au>He, Daquan</au><au>Li, Zhaohuai</au><au>Chen, Binyao</au><au>Zhu, Lei</au><au>Su, Wenru</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intravitreal dexamethasone implants facilitate the management of refractory Behçet's uveitis with vasculitis</atitle><jtitle>Clinical immunology (Orlando, Fla.)</jtitle><addtitle>Clin Immunol</addtitle><date>2023-06</date><risdate>2023</risdate><volume>251</volume><spage>109633</spage><epage>109633</epage><pages>109633-109633</pages><artnum>109633</artnum><issn>1521-6616</issn><eissn>1521-7035</eissn><abstract>To investigate the efficacy and safety of dexamethasone (DEX) implant, Ozurdex ®, as an adjunctive treatment for refractory Behçet's uveitis (BU), a total of 61 patients (80 eyes) were included in this cross-sectional study and divided into the non-DEX and DEX groups. After >12 months of treatment, the improvement in the fluorescein angiography score and vitritis score was significantly higher in the DEX group than in the non-DEX group. Although the posterior capsule opacification score was exacerbated, the rate of low-dose systemic glucocorticoid was higher and the relapse times were fewer in the DEX group. Therefore, Ozurdex® is an effective and safe option for patients with BU that are refractory to systemic immunosuppressant treatments by controlling vasculitis, stabilizing vitreous inflammation, preventing recurrence, and reducing daily glucocorticoid doses.
•Dexamethasone intravitreal implants are an effective and safe option for glucocorticoid-resistant Behcet's uveitis.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>37150241</pmid><doi>10.1016/j.clim.2023.109633</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1521-6616 |
| ispartof | Clinical immunology (Orlando, Fla.), 2023-06, Vol.251, p.109633-109633, Article 109633 |
| issn | 1521-6616 1521-7035 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2811215838 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Behcet Syndrome - complications Behcet Syndrome - drug therapy Behçet's disease Cross-Sectional Studies Dexamethasone Dexamethasone - therapeutic use Glucocorticoids - therapeutic use Humans Ozurdex Retrospective Studies Treatment Outcome Uveitis Uveitis - drug therapy Vasculitis |
| title | Intravitreal dexamethasone implants facilitate the management of refractory Behçet's uveitis with vasculitis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T03%3A56%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intravitreal%20dexamethasone%20implants%20facilitate%20the%20management%20of%20refractory%20Beh%C3%A7et's%20uveitis%20with%20vasculitis&rft.jtitle=Clinical%20immunology%20(Orlando,%20Fla.)&rft.au=Tao,%20Tianyu&rft.date=2023-06&rft.volume=251&rft.spage=109633&rft.epage=109633&rft.pages=109633-109633&rft.artnum=109633&rft.issn=1521-6616&rft.eissn=1521-7035&rft_id=info:doi/10.1016/j.clim.2023.109633&rft_dat=%3Cproquest_cross%3E2811215838%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2811215838&rft_id=info:pmid/37150241&rft_els_id=S1521661623001328&rfr_iscdi=true |